News and Events

July 9, 2024
Scientists from Weill Cornell Medicine and the Dana-Farber Cancer Institute in Boston have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a rapidly growing field that uses high-resolution digital images created from tissue samples to help diagnose disease and guide treatment.
June 27, 2024
Weill Cornell Medicine received a $1.5 million grant from the U.S. Department of Defense Prostate Cancer Research Program to develop new approaches for predicting the spread of cancer cells to the bone in men with prostate cancer, using tumor samples taken at early stages of the disease.
May 29, 2024
Research led by Weill Cornell Medicine provides new evidence that most colorectal cancers begin with the loss of intestinal stem cells, even before cancer-causing genetic alterations appear. The results, published on May 29 in Developmental Cell, overturn the prevailing theory for colorectal tumor initiation and suggest new ways to diagnose the disease before it has a chance to become established.
May 10, 2024
A team led by Dr. Eddie Imada, assistant professor of research in pathology and laboratory medicine, has been awarded a three-year, $1.5 million United States Department of Defense grant for research on a cellular process called alternative polyadenylation and its role in prostate cancer.
April 23, 2024
 Weill Cornell Medicine investigators have uncovered a way to unleash in blood vessels the protective effects of a type of fat-related molecule known as a sphingolipid, suggesting a promising new strategy for the treatment of coronary artery disease.
April 16, 2024
Cinthia Garcia was always passionate about science and medicine. The first in her family to complete post-secondary education, she earned a Bachelor of Science degree at Emmanuel College in Boston in 2018 and then became a laboratory manager at the UC San Diego School of Medicine. Still, she dreamed of a career as a physician-scientist, pursuing translational research with the potential to improve patient care.
March 27, 2024
Read the latest WCM Pathology Newsletter to learn more about our Research Highlights, Scholarly Advances, new faculty and much more. You can also read our past issues here.
March 18, 2024
Researchers at Weill Cornell Medicine have performed the most comprehensive analysis to date of cancer of the ureters or the urine-collection cavities in the kidney, known as upper tract urothelial carcinoma (UTUC).  The study, which compared the characteristics of primary and metastatic tumors, provides new insights into the biology of these aggressive cancers and potential ways to treat them.
March 6, 2024
Dr. Nuzzo received two prestigious awards - the ESMO Merit Travel Grant and the ESMO TAT Award for Best Poster - with the abstract "Targeting de novo lipogenesis synergizes with androgen receptor inhibitors in castration-resistant prostate cancer".
March 4, 2024
Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators. They have conducted the first whole genome sequencing analysis of male breast cancer, which looked at the complete DNA landscape of tumor samples from 10 patients.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700